A retrospective electronic health record-derived study supporting the accelerated approval of a new drug for mantle cell lymphoma in the U.S.

Eli Lilly researchers, led by Dr. Lisa Hess, analyzed de-identified Flatiron EHR data to understand treatment patterns after covalent BTKi therapy in mantle cell lymphoma, an area lacking clinical guidance. Among 1,150 eligible patients, the study found significant heterogeneity in post-cBTKi treatment, with a median time to next treatment, failure, or death of 3.0 months and median overall survival of 13.2 months. These findings demonstrated substantial unmet need and supported FDA accelerated approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma.

Flatiron Health is a Roche-owned company supplying EHR-derived oncology real-world data, captured at the source through its own OncoEMR software.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.